Organs-on-chips Market - Type [Product (Liver, Lung, Heart, Kidney), Service], Material (PDMS, Polymer, Glass), Model Type (Single, Multi-organ), Application (Drug Discovery, Toxicity Testing, Personalized Medicine), End-user, Global Forecast 2024 – 2032

Organs-on-chips Market Size

Organs-on-chips Market was valued at USD 116.5 million in 2023 and is estimated to witness 32.2% CAGR from 2024 to 2032. The market has witnessed significant growth and innovation in recent years, driven by the increasing demand for more accurate and reliable in-vitro models of human organs for drug discovery, toxicity testing, and disease modelling.
 

These microfluidic devices hold the potential to revolutionize the pharmaceutical and healthcare industries by offering the more physiologically relevant research and development (R&D) platforms. Additionally, organs-on-a-chip technology offers a significant benefit by potentially minimizing the need for animals in medical research, aligning with ethical practices.
 

For instance, the Humane Society International, reported that over 115 million animals are used for clinical testing worldwide, a number that could substantially decrease with organ-on-chip technology. The organ-on-chip system's capability to replicate human organs affordably positions it as a highly promising tool as a non-animal alternative testing for drug discovery contributing to compelling market growth.
 

Organ-on-chip refers to a microfluidic system that replicates the physiological and functional characteristics of human organs on a microscale platform. The bioengineered chips mimic the complexities of organs, supporting the accurate representation of drug responses, disease mechanisms, and tissue interactions with unprecedented accuracy. Organ-on-chip systems integrate living cells and microfluidic channels, creating a realistic in-vitro environment for advanced research and development applications.
 

Organs-on-chips Market Trends

The rising prevalence of chronic diseases has led to an increased need for rapid drug discovery methods, growing the necessity for drug toxicity identification, technological progress, and the introduction of new products by major market players. For example, the COVID-19 pandemic had positively influenced the market in investigating the lung’s pathophysiology in patients. For instance, Emulate Inc.'s alveolus lung-chip and airway lung-chip models, played a crucial role in COVID-19 research. These innovative organ-on-chip technology supported in enhancing the early infectious disease clinical studies expediting the pandemic research efforts.
 

• In February 2023, CN Bio introduced the PhysioMimix single-organ higher throughput (HT) system, overcoming the adoption barriers in drug discovery workflows. The launch aimed to expand the drug discovery service capabilities, facilitating larger-scale studies for lead candidate drugs.
   
• Additionally, the growing advancement and the support by the regulatory authorities aimed in accelerating the development and adoption of the advanced organ-on-chip technologies. For instance, FDA Modernization Act 2.0 approval in January 2023 aimed to accelerate the organ-on-chip integration in pharmaceuticals, utilizing innovations in testing methods for ethical and streamlined drug development. The advanced technology provided an opportunity for the pharmaceutical industry to expedite drug development, reducing reliance on animal studies.
   
• Thus, these innovations in organ-on-chip technology hold immense promise for drug development, personalized medicine, and understanding complex biological processes, offering a more ethical and efficient alternative to traditional animal testing. Therefore, the convergence of the aforementioned drivers highlighted the increasing demand for organ-on-chip technology in the coming years.
   

However, a significant challenge for market is the intricate task of reproducing comprehensive organ functionalities, establishing standardized protocols, and obtaining regulatory acceptance. These challenges represent significant constraints impeding the growth of the market.
 

Organs-on-chips Market Analysis

Based on the type, the global organs-on-chips market is classified into product and service. The product segment is expected to dominate contributing significantly to revenue of USD 81.3 million in 2023 and poised to exhibit dominance throughout the forecast period.
 

• The product segment is further sub-segmented into liver-on-chip, lung-on-chip, heart-on-chip, kidney-on-chip, and other organ chips.
   
• The lung-on-chip secured a substantial market share, driven by increased demand during the pandemic due to its applications. The precise prediction of airborne nanoparticle absorption and accurate replication of the inflammatory response to microbial pathogens showcased the widespread adoption for the lung-on-chip model.
   
• Furthermore, the global prevalence of pulmonary diseases, especially tuberculosis, has surged the demand for effective disease management, contributing to market growth. According to the WHO Global Tuberculosis Report 2022, around 10.6 million tuberculosis cases were found in 2021 worldwide, with a predicted 3.6% increase from 2020 to 2021.The surged demand for tuberculosis management through organ-on-chip technology is expected to fuel the market expansion.

Based on material, the organ on chip market is classified into polydimethylsiloxane (PDMS), polymer, and glass. The PDMS is expected hold the highest market share of 46.2% in 2023.
 

• The microfluidic organ-on-chip platform using PDMS has rapidly gained popularity and widespread adoption owing to its compatibility with high-resolution microstructures and nanostructures through replica molding.
   
• In addition, PDMS has been widely recognized for its biocompatibility, optical transparency, and gas permeability, making it well-suited for biological applications. Its elasticity also facilitated effective mechanical stimulation of cells witnessing as a promising tool for the next generation in-vitro models.

Based on model type, the organs-on-chips market is classified into single-organ model and multi-organ model. In 2023, the single-organ model dominated the market anticipating its growth during the analysis period with a CAGR of 32%
 

• The popularity of single-organ models in the market is attributed to their specificity and focused applications. These models include liver-on-chip, lung-on-chip, heart-on-chip, and other chips provide comprehensive insights into specific organ functions, proving influential in drug development, disease modeling, and other applications.
   
• The single-organ model maintained the capability to replicate organ-level responses in a controlled environment, leading to the widespread adoption witnessing its dominance in driving advancements in organ-on-chip technology.
   

Based on applications, the organs-on-chips market is categorized into drug discovery, toxicity testing, disease modelling, personalized medicine, and other applications. The drug discovery is expected to lead the market, projecting the highest revenue of USD 476.8 million by 2032.
 

• The challenges in novel drug discovery, characterized by rising R&D costs and a low success rate in clinical trials, spurred the demand for advanced and precise predictive preclinical in-vitro models.
   
• Prominent market players are strategically advancing organ-on-chip technology to address the demand for cost-effective processes and explore market opportunities. For instance, in October 2023, Harvard University's Wyss Institute partnered with the Biomedical Advanced Research and Development Authority (BARDA) to elevate the human organ chip platform, with a focus on its potential in radiation exposure research. This strategic collaboration aimed in enhancing the research capabilities, secured funding support, and accelerated the drug discovery.
   

Based on end-user, the organs-on-chips market is classified into pharmaceutical and biotechnology companies, academic and research institutes, and other end-users. The pharmaceutical and biotechnology companies segment is held the highest market share of 63% in 2023.
 

• The pharmaceutical and biotechnology companies are actively seeking innovative solutions to bridge the translational gap between preclinical and clinical drug development, aiming to reduce attrition rates.
   
• The companies are leading in substantial investments, prioritize R&D, focused on personalized medicine, and consistently new product launches. Their focus on enhancing preclinical testing efficiency aligned with the market's demand for advanced and predictive in-vitro models.
   
• For instance, in September 2020, Javelin Biotech entered into a three-year collaboration with Pfizer Inc. to develop an innovative "Organ-on-a-Chip" predictive pharmacokinetics platform. The integrated platform aimed in accelerating the study of pharmacokinetic properties for small molecules using cutting-edge technology.

In 2023, North America secured a substantial market share in the organs-on-chips market and is expected to dominate throughout the forecast period.
 

• The dominance is boosted by escalated R&D expenditures in drug discovery and biotechnology in addition to the key market players presence and government initiatives.
   
• Additionally, the rising prevalence of chronic diseases is a driving factor. For instance, in June 2023, the FDA granted a partial option award to further propel the development of organ chips for radiation countermeasure research, evaluating efficacy and screening experimental compounds for Medical Countermeasures (MCM). Similarly, in 2021, responding to the COVID-19 pandemic, the FDA collaborated with the National Institute of Allergy and Infectious Diseases (NIAID) to advance organ-on-chip and microphysiological systems (MPS) models. This collaboration aimed in facilitating the development and assessment of Medical Countermeasures (MCMs) for COVID-19.
   
• Furthermore, growing investments by the public and private institutes, exemplified by the National Institutes of Health (NIH) funding for biotechnology, signified the continuous growth trajectory. In 2021, NIH estimated research funding for biotechnology in the U.S. at USD 7,847 million, projected to increase to USD 8,142 million in 2022. This upward trend in research funding anticipated a sustained growth, supporting organ-on-chip technology research and propelling market expansion in the foreseeable future.
   

Organs-on-chips Market Share

The market featured an intense competition among key players. Leading key players focusing on R&D, product innovation, and strategic collaborations to gain a competitive edge, driven by the growing demand for advanced in-vitro models.
 

Organs-on-chips Market Companies

Prominent players operating in the organs-on-chips industry are as mentioned below:

• Altis Biosystems
• AlveoliX AG
• Axosim
• Bi/ond Solutions B.V
• Cherry Biotech
• CN-Bio
• Emulate, Inc.
• Hesperos, Inc.
• Insphero
• MesoBioTech
• Mimetas B.V.
• Nortis Inc.
• React4Life
• TARA Biosystems (Valo Health)
• TissUse GmbH
   

Organs-on-chips Industry News:

• In September 2023, NETRI unveiled an innovative series of organ-on-chip kits for efficient in-vitro modelling for the peripheral nervous system. These devices were intricately designed to accommodate cells from diverse species. The launch aimed in expanding NETRI's organ-on-chip portfolio with Axol Bioscience's iPSC neurons capability, reinforcing their commitment to innovation.
   
• In June 2023, Emulate, Inc., introduced the Emulate Chip-A1 Accessible Chip via an early access program. This chip enabled the efficient modelling of intricate 3D tissues like the tumor microenvironment and skin, with direct compound dosing capabilities. The product launch aimed in, expanding the capabilities of organ-on-a-chip technology to reach new dimensions of tissue modelling.
   

The organ on chip market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Product
  • Liver-on-chip
  • Lung-on-chip
  • Heart-on-chip
  • Kidney-on-chip
  • Other products
• Service

Market, By Material

• Polydimethylsiloxane (PDMS)
• Polymer
• Glass

Market, By Model Type

• Single-organ model
• Multi-organ model

Market, By Application

• Drug discovery
• Toxicity testing
• Disease modeling
• Personalized medicine
• Other applications

Market, By End-user

• Pharmaceutical and biotechnology companies
• Academic and research institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa